RESUMEN
Introduction: Muscovy duck parvovirus (MDPV), Goose parvovirus (GPV), Duck circovirus, (DuCV) and Duck adenovirus 3 (DAdV-3) are important pathogens that cause high morbidity and mortality in ducks, causing huge economic loss for the duck industry. Methods: The present study, a quadruplex one-step real time quantitative PCR method for the detection of MDPV, GPV, DuCV, and DAdV-3 was developed. Results: The results showed that assay had no cross-reactivity with other poultry pathogens [Duck plague virus (DPV), Duck tembusu virus (DTMUV), H6 avian influenza virus (H6 AIV), New duck reovirus (NDRV), Newcastle disease virus (NDV), H4 avian influenza virus (H4 AIV), Escherichia coli (E. coli), Muscovy duck reovirus (MDRV), Egg drop syndrome virus (EDSV), Pasteurella multocida (P. multocida)]. The sensitivity result showed that the limits of detection for MDPV, GPV, DuCV, and DAdV-3 were 10, 10, 1 and 10 copies/µl, respectively; The coefficients of variation intra- and inter-method was 1-2%; The range of linear (109 to 103 copies/µL) demonstrated the R2 values for MDPV, GPV, DuCV, and DAdV-3 as 0.9975, 0.998, 0.9964, and 0.996, respectively. The quadruplex real time quantitative PCR method efficiency was 90.30%, 101.10%, 90.72%, and 90.57% for MDPV, GPV, DuCV, and DAdV-3, respectively. 396 clinical specimens collected in some duck sausages from June 2022 to July 2023 were simultaneously detected using the established quadruplex real time quantitative PCR method and the reported assays. The detection rates for MDPV, GPV, DuCV, and DAdV-3 were 8.33% (33/396), 17.93% (71/396), 33.58% (133/396), and 29.04% (115/396), respectively. The agreement between these assays was greater than 99.56%. Discussion: The developed quadruplex real-time quantitative PCR assay can accurately detect these four viruses infecting ducks, providing a rapid, sensitive, specific and accurate technique for clinical testing.
Asunto(s)
Patos , Enfermedades de las Aves de Corral , Reacción en Cadena en Tiempo Real de la Polimerasa , Animales , Patos/virología , Reacción en Cadena en Tiempo Real de la Polimerasa/métodos , Enfermedades de las Aves de Corral/virología , Enfermedades de las Aves de Corral/diagnóstico , Sensibilidad y Especificidad , Parvovirinae/genética , Parvovirinae/aislamiento & purificación , Parvovirinae/clasificación , Aviadenovirus/genética , Aviadenovirus/aislamiento & purificación , Aviadenovirus/clasificación , Circovirus/genética , Circovirus/aislamiento & purificación , Circovirus/clasificación , Infecciones por Parvoviridae/veterinaria , Infecciones por Parvoviridae/diagnóstico , Infecciones por Parvoviridae/virologíaRESUMEN
Nonepisodic angioedema with eosinophilia (NEAE) is characterised by a single episode of angioedema localised to the extremities and peripheral eosinophilia. While NEAE can develop in response to infection or vaccination, NEAE associated with acute parvovirus B19 (B19V) infection is rare. We describe the case of a young woman with NEAE that developed during acute B19V infection. She presented with 1-week history of pruritus and polyarthralgia in the extremities, followed by the development of peripheral oedema, and was positive for anti-B19V IgM antibody. Her arthralgia improved within 2 weeks without any specific intervention; however, the oedema and pruritic erythema persisted and the peripheral eosinophil count increased. A short course of prednisolone therapy for suspected NEAE alleviated the symptoms, which have not recurred for more than 2 years. Thus, we believe that the patient was affected by NEAE and that NEAE can develop following acute B19 infection.
Asunto(s)
Angioedema , Eosinofilia , Parvovirus B19 Humano , Humanos , Femenino , Parvovirus B19 Humano/inmunología , Angioedema/tratamiento farmacológico , Angioedema/virología , Angioedema/diagnóstico , Eosinofilia/tratamiento farmacológico , Eosinofilia/virología , Eosinofilia/complicaciones , Prednisolona/uso terapéutico , Adulto , Eritema Infeccioso/complicaciones , Eritema Infeccioso/diagnóstico , Infecciones por Parvoviridae/complicaciones , Infecciones por Parvoviridae/diagnóstico , Infecciones por Parvoviridae/tratamiento farmacológico , Artralgia/etiología , Artralgia/virología , Enfermedad AgudaRESUMEN
BACKGROUND: Plastic bronchitis (PB) is an uncommon and severe acute respiratory ailment characterized by the formation of casts in the trachea or bronchial tree. Some instances have been linked to human bocavirus (HBoV) infections. CASE PRESENTATION: In this report, we present a case of PB secondary to HBoV1 infection in a previously healthy pediatric patient. A 17-month-old male was admitted due to respiratory distress following 2 days of cough and fever. A preadmission chest X-ray revealed atelectasis of the left lung. Emergency electronic bronchoscopy and foreign body forceps were employed to remove casts, leading to improved breathing. High-throughput next-generation sequencing detected only HBoV1. A subsequent electronic bronchoscopy 2 days later showed no casts. CONCLUSIONS: PB associated with HBoV1 infection should be considered in children experiencing acute respiratory distress, and a second bronchoscopy intervention may not be necessary in cases related to HBoV1.
Asunto(s)
Bronquitis , Broncoscopía , Secuenciación de Nucleótidos de Alto Rendimiento , Bocavirus Humano , Infecciones por Parvoviridae , Humanos , Masculino , Bronquitis/virología , Bronquitis/diagnóstico , Lactante , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Bocavirus Humano/aislamiento & purificación , Bocavirus Humano/genética , Infecciones por Parvoviridae/diagnóstico , Infecciones por Parvoviridae/virología , Broncoscopía/métodosAsunto(s)
Parvovirus B19 Humano , Complicaciones Infecciosas del Embarazo , Humanos , Femenino , Embarazo , Parvovirus B19 Humano/inmunología , Complicaciones Infecciosas del Embarazo/diagnóstico , Complicaciones Infecciosas del Embarazo/epidemiología , Complicaciones Infecciosas del Embarazo/virología , Complicaciones Infecciosas del Embarazo/sangre , Europa (Continente)/epidemiología , Infecciones por Parvoviridae/epidemiología , Infecciones por Parvoviridae/diagnóstico , Infecciones por Parvoviridae/sangre , Eritema Infeccioso/diagnóstico , Eritema Infeccioso/epidemiología , Adulto , EpidemiasRESUMEN
Human parvovirus B19 (HPVB19) belongs to Parvoviridae, a genus of erythrovirus, and has been associated with various human diseases, and HPVB19 infection is one of the most important causes of refractory anemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study retrospectively analyzed 24 patients with HSCT combined with HPVB19 infection to collate and summarize the clinical presentation, treatment, and regression of patients with combined HPVB19 infection after allo-HSCT and provide experience in the management of HPVB19 infection after allo-HSCT. The median age of the patients with HPVB19 infection was 25 years, and the median time of infection occurrence was +107 days after transplantation, and 22 (91.7% ) had anemia with a median hemoglobin (HGB) level of 77.5 (46-149) g/L, and 13 (54.2% ) had new-onset anemia or persistent decline in HGB. The median length of hospital stay was 19 days. Among patients with new-onset anemia or persistent decline in HGB, the mean increase in HGB after treatment with intravenous immunoglobulin and/or antiviral therapy was 15.69 g/L, and treatment was effective in 10 (76.92% ) patients. HPVB19 infection should be alerted to the development of refractory anemia after HSCT; despite the lack of specific treatment, the overall prognosis of HPVB19-infected patients is good.
Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Infecciones por Parvoviridae , Parvovirus B19 Humano , Humanos , Adulto , Estudios Retrospectivos , Parvovirus B19 Humano/aislamiento & purificación , Masculino , Adulto Joven , Femenino , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Adolescente , Persona de Mediana Edad , Infecciones por Parvoviridae/diagnóstico , Trasplante Homólogo , NiñoRESUMEN
In line with European trends, since 2023 Lombardy (Northern Italy) is experiencing a resurgence of measles and an increased number of reported cases of fever and rash. Measles discarded cases observed in our region within the context of measles and rubella surveillance from the first few months of 2024 (N = 30) were investigated for parvovirus B19 (B19V) and other rash-associated viruses. Thirteen cases tested positive for B19V DNA, representing a significant increase from previous years (on average 3 cases per year, p < 0.001) and ~40% of all B19V DNA-positive patients we detected since 2017. In 2024, B19V DNA-positive subjects spanned all ages, and the virus was predominant among adolescents and adults (84.6%). Two B19V infected patients were hospitalised, and likely cross-reacting anti-measles virus IgM were found in both. Our data align with the recent reports from the ECDC and various European countries, which are experiencing a surge in B19V infections, and underline the importance of comprehensive measles and rubella surveillance systems that can adapt to changing epidemiological trends.
Asunto(s)
Sarampión , Parvovirus B19 Humano , Rubéola (Sarampión Alemán) , Humanos , Italia/epidemiología , Parvovirus B19 Humano/genética , Parvovirus B19 Humano/aislamiento & purificación , Parvovirus B19 Humano/inmunología , Sarampión/epidemiología , Sarampión/diagnóstico , Sarampión/virología , Rubéola (Sarampión Alemán)/epidemiología , Rubéola (Sarampión Alemán)/diagnóstico , Rubéola (Sarampión Alemán)/virología , Femenino , Masculino , Adulto , Adolescente , Adulto Joven , Niño , Diagnóstico Diferencial , Preescolar , Infecciones por Parvoviridae/epidemiología , Infecciones por Parvoviridae/diagnóstico , Anticuerpos Antivirales/sangre , Persona de Mediana Edad , Lactante , ADN Viral/genética , Inmunoglobulina M/sangreRESUMEN
BACKGROUND: This study investigated clinical and laboratory characteristics of human bocavirus type 1 (HBoV1)-plastic bronchiolitis (PB), Mycoplasma pneumoniae (MP)-associated plastic bronchitis (PB) and MP-NPB in children, highlighting inflammation, coagulation, and bronchoscopic needs. METHODS: Data on preschool children with PB during HBoV1 or MP infection were collected, comparing MP-PB to severe Mycoplasma pneumoniae pneumonia. RESULT: Compared with the MP-PB group, the HBoV1-PB group, with younger children, had significantly milder clinical symptoms but higher WBC counts (p = .028). The MP-PB group exhibited notably elevated Fibrinogen (p = .045) and d-dimer levels (p < .001). When contrasting the MP-PB with the MP-NPB group, children in MP-PB group still had higher levels of d-dimer and increased inflammatory indicators such as C-reactive protein, procalcitonin, lactate dehydrogenase, and interleukin-6, which were significantly elevated compared with the MP-NPB group. MP-PB showed a higher prevalence of plastic bronchial casts in lower lobes (p = .016) and a dominance of neutrophils in BALF cytology. Additionally, children in the MP-PB group tended to undergo a greater number of bronchoscopies. CONCLUSION: This study identifies key differences in plastic bronchitis in children due to HBoV1 and MP, highlighting HBoV1's milder inflammation in younger kids and MP's link to severe inflammatory and coagulation responses, guiding clinical diagnosis and treatment.
Asunto(s)
Bronquitis , Mycoplasma pneumoniae , Neumonía por Mycoplasma , Humanos , Preescolar , Masculino , Femenino , Bronquitis/microbiología , Bronquitis/diagnóstico , Bronquitis/virología , Neumonía por Mycoplasma/sangre , Neumonía por Mycoplasma/inmunología , Lactante , Infecciones por Parvoviridae/inmunología , Infecciones por Parvoviridae/complicaciones , Infecciones por Parvoviridae/diagnóstico , Bocavirus Humano , Bronquiolitis/virología , Bronquiolitis/microbiología , Niño , Líquido del Lavado Bronquioalveolar/virología , Líquido del Lavado Bronquioalveolar/microbiología , Productos de Degradación de Fibrina-Fibrinógeno/análisis , Productos de Degradación de Fibrina-Fibrinógeno/metabolismo , Proteína C-Reactiva/análisisRESUMEN
A 19-year-old male patient with high-risk acute B-cell lymphoblastic leukemia received haploidentical stem cell transplantation. He developed anemia repeatedly and parvovirus B19 nucleic acid was positive in blood plasma. The patient was diagnosed with cold agglutinin syndrome and multiple organ dysfunction including respiratory failure and hepatitis. In the conflict between viral infection and the treatment of cold agglutinin syndrome, we provided supportive treatment, complement inhibitors to control hemolysis, and antiviral therapy. After timely glucocorticoid and immunosuppressant therapy, the patient had achieved a good response.
Asunto(s)
Insuficiencia Multiorgánica , Parvovirus B19 Humano , Humanos , Masculino , Adulto Joven , Insuficiencia Multiorgánica/etiología , Insuficiencia Multiorgánica/virología , Infecciones por Parvoviridae/complicaciones , Infecciones por Parvoviridae/diagnóstico , Anemia Hemolítica/etiología , Anemia Hemolítica/diagnóstico , Anemia Hemolítica Autoinmune/terapiaRESUMEN
Potential prognostic indicators have been associated with decreased survival during canine parvoviral enteritis (CPE), such as body weight, sex, and clinicopathological parameters. Few studies reported the prognostic factors for CPE in Italy; therefore, the aim of this study was to identify prognostic factors associated with the survival of dogs admitted to the Veterinary Teaching Hospital of Perugia University, naturally infected with canine parvovirus. Seventy-six medical records of dogs with a definitive diagnosis of parvoviral infection admitted from 2017 to 2021 have been reviewed and included in the study. From medical records were extracted data on signalment, history, clinical examination, hematology, serum biochemistry, treatments, progression of clinical signs during hospitalization and outcome. The data have been subjected to univariate and multivariate statistical analysis. Our results showed winter season, male sex, dog ownership, small breed, normal sensory status, normal heart rate, normal hydration status, abdominal pain, increased capillary reperfusion time, and normal white blood cell count as positive prognostic factors. The survival model confirmed that parameters such as male sex, small breed, and ownership increased the survival rate during hospitalization. Data reported in the present study are partially in agreement with previous studies and added new information on the possible prognostic factors in dogs affected by CPE in Italy.
Asunto(s)
Enfermedades de los Perros , Enteritis , Hospitales Veterinarios , Hospitales de Enseñanza , Infecciones por Parvoviridae , Italia , Estudios Retrospectivos , Parvovirus Canino , Enteritis/diagnóstico , Enteritis/epidemiología , Enteritis/veterinaria , Enfermedades de los Perros/diagnóstico , Enfermedades de los Perros/epidemiología , Pronóstico , Análisis de Supervivencia , Factores de Riesgo , Infecciones por Parvoviridae/diagnóstico , Infecciones por Parvoviridae/epidemiología , Infecciones por Parvoviridae/veterinaria , Animales , PerrosRESUMEN
Canine parvovirus (CPV) is one of the main pathogens causing toxic diarrhea in Chinese dogs, is the cause of large-scale epidemic of dogs, and poses a great threat to the dog industry in China. Rapid, sensitive, and specific CPV testing facilitates the timely diagnosis and treatment of sick dogs. The aim of this study was to build a LAMP-CRISPR/Cas12b platform for CPV detection. The loop mediated isothermal amplification (LAMP) technique was combined with CRISPR-Cas12b analysis to establish a "two-step" and "one-tube" CRISPR/Cas12b rapid CPV method, respectively. The detection system was constructed with specific LAMP primers and single guide RNA (sgRNA) for the highly conserved short fragment of the CPV gene, which could be detected within 1 h without cross-reaction with the other viruses causing canine diarrhea. The detection limits of both "two-step" and "one-tube" CRISPR/Cas12b reactions were 10-1 copies per µL, which was 100 times more sensitive than qPCR and LAMP. In order to achieve point-of-care testing (POCT) of CPV, a one-tube LAMP-CRISPR/Cas12b nucleic acid extraction and detection platform based on magnetic nanoparticle enrichment technology was established to achieve "sample in-result out". The results of this method for simulated samples were compared with those of quantitative real-time PCR; the results showed 100% consistency, and the time was shorter, which could be used to detect the diseased dogs earlier and provide a basis for clinical diagnosis. The LAMP-CRISPR/Cas12b method established in this study provides a sensitive and specific method for rapid detection of CPV, and provides technical support for rapid diagnosis of CPV.
Asunto(s)
Sistemas CRISPR-Cas , Técnicas de Amplificación de Ácido Nucleico , Infecciones por Parvoviridae , Parvovirus Canino , Animales , Parvovirus Canino/genética , Parvovirus Canino/aislamiento & purificación , Perros , Sistemas CRISPR-Cas/genética , Técnicas de Amplificación de Ácido Nucleico/métodos , Técnicas de Amplificación de Ácido Nucleico/veterinaria , Infecciones por Parvoviridae/veterinaria , Infecciones por Parvoviridae/diagnóstico , Infecciones por Parvoviridae/virología , Enfermedades de los Perros/virología , Enfermedades de los Perros/diagnóstico , Técnicas de Diagnóstico Molecular/métodos , Técnicas de Diagnóstico Molecular/veterinaria , Sensibilidad y Especificidad , Límite de DetecciónRESUMEN
We report an epidemic of parvovirus B19 infections in Denmark during the first quarter of 2024, with a peak incidence 3.5 times higher than during the most recent epidemic in 2017. In total, 20.1% (130/648) of laboratory-confirmed cases were pregnant. Severe adverse outcomes were observed among 12.3% (16/130) of pregnant people and included foetal anaemia, foetal hydrops and miscarriage. Parvovirus B19 infection is not systematically monitored, but a national laboratory-based surveillance system is currently being established in Denmark.
Asunto(s)
Infecciones por Parvoviridae , Parvovirus B19 Humano , Complicaciones Infecciosas del Embarazo , Humanos , Femenino , Embarazo , Dinamarca/epidemiología , Parvovirus B19 Humano/aislamiento & purificación , Complicaciones Infecciosas del Embarazo/epidemiología , Complicaciones Infecciosas del Embarazo/diagnóstico , Complicaciones Infecciosas del Embarazo/virología , Adulto , Incidencia , Infecciones por Parvoviridae/epidemiología , Infecciones por Parvoviridae/diagnóstico , Epidemias , Hidropesía Fetal/epidemiología , Hidropesía Fetal/virología , Índice de Severidad de la Enfermedad , Adulto Joven , Eritema Infeccioso/epidemiología , Eritema Infeccioso/diagnóstico , Adolescente , Aborto Espontáneo/epidemiología , Aborto Espontáneo/virología , Vigilancia de la PoblaciónRESUMEN
From April 2023 to May 2024, an unusual epidemic of parvovirus B19 (B19V) infections occurred in France. The number of B19V IgM-positive serologies was four times higher than in the previous epidemic in 2019. Clinical data from emergency networks corroborated this observation. Morbidity and mortality consequences were observed in children through all data sources. In adults, the increase was only observed in laboratory-confirmed data. Physicians and decisionmakers should be informed in order to better prevent, diagnose and manage at-risk patients.
Asunto(s)
Brotes de Enfermedades , Inmunoglobulina M , Infecciones por Parvoviridae , Parvovirus B19 Humano , Humanos , Francia/epidemiología , Parvovirus B19 Humano/aislamiento & purificación , Adulto , Femenino , Masculino , Niño , Infecciones por Parvoviridae/epidemiología , Infecciones por Parvoviridae/diagnóstico , Inmunoglobulina M/sangre , Adolescente , Preescolar , Persona de Mediana Edad , Anticuerpos Antivirales/sangre , Eritema Infeccioso/epidemiología , Eritema Infeccioso/diagnóstico , Adulto Joven , Lactante , AncianoRESUMEN
A 13-year-old girl who had a kidney transplant four weeks prior presented with a 10-day history of fatigue, paleness, and headache. On physical examination, tachycardia and paleness were noted. Laboratory testing was notable for severe anemia and mild leukopenia and thrombocytopenia. Polymerase chain reaction (PCR) test for Epstein-Barr virus (EBV) and cytomegalovirus (CMV) were negative and for parvovirus B19 (PVB19) was positive. Despite lower immunosuppression and administration of intravenous immunoglobulin (IVIG) it persisted for 15 months, and frequent red blood cell transfusions were needed. PVB19 is a less common but significant complication. The patient's clinical course demonstrates the importance of this complication and the challenges in its management. A notable void exists in the literature regarding standardized treatment protocols for PVB19-induced recurrent anemia after kidney transplant. This case indicates the need for further research and consensus to guide effective clinical interventions in similar cases.
Asunto(s)
Anemia , Trasplante de Riñón , Infecciones por Parvoviridae , Parvovirus B19 Humano , Humanos , Trasplante de Riñón/efectos adversos , Femenino , Parvovirus B19 Humano/aislamiento & purificación , Adolescente , Anemia/etiología , Anemia/terapia , Anemia/virología , Anemia/diagnóstico , Infecciones por Parvoviridae/diagnóstico , Infecciones por Parvoviridae/complicaciones , Inmunoglobulinas Intravenosas/uso terapéutico , Recurrencia , Transfusión de Eritrocitos , Inmunosupresores/uso terapéutico , Inmunosupresores/efectos adversosRESUMEN
PURPOSE OF REVIEW: Viral infections continue to burden allogeneic hematopoietic cell transplant (HCT) recipients. We review the epidemiology, diagnosis, and management of human herpesvirus (HHV)-6, HHV-8 and parvovirus B19 following HCT. RECENT FINDINGS: Advances in HCT practices significantly improved outcomes but impact viral epidemiology: post-transplant cyclophosphamide for graft-versus-host disease prevention increases HHV-6 reactivation risk while the impact of letermovir for CMV prophylaxis - and resulting decrease in broad-spectrum antivirals - is more complex. Beyond the well established HHV-6 encephalitis, recent evidence implicates HHV-6 in pneumonitis. Novel less toxic therapeutic approaches (brincidofovir, virus-specific T-cells) may enable preventive strategies in the future. HHV-8 is the causal agent of Kaposi's sarcoma, which is only sporadically reported after HCT, but other manifestations are possible and not well elucidated. Parvovirus B19 can cause severe disease post-HCT, frequently manifesting with anemia, but can also be easily overlooked due to lack of routine screening and ambiguity of manifestations. SUMMARY: Studies should establish the contemporary epidemiology of HHV-6, and other more insidious viruses, such as HHV-8 and parvovirus B19 following HCT and should encompass novel cellular therapies. Standardized and readily available diagnostic methods are key to elucidate epidemiology and optimize preventive and therapeutic strategies to mitigate the burden of infection.
Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Herpesvirus Humano 6 , Herpesvirus Humano 8 , Parvovirus B19 Humano , Humanos , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Parvovirus B19 Humano/aislamiento & purificación , Infecciones por Parvoviridae/epidemiología , Infecciones por Parvoviridae/diagnóstico , Antivirales/uso terapéutico , Infecciones por Roseolovirus/epidemiología , Infecciones por Roseolovirus/virología , Infecciones por Roseolovirus/diagnóstico , Trasplante Homólogo/efectos adversos , Infecciones por Herpesviridae/epidemiología , Infecciones por Herpesviridae/virologíaRESUMEN
Importance: Although the risk of parvovirus B19 infection during pregnancy and subsequent risk of adverse fetal outcome are low, understanding management practices is essential for proper treatment of fetuses with nonimmune hydrops fetalis. In addition, continued investigation into delivery management, breastfeeding recommendations, and congenital abnormalities associated with pregnancies complicated by parvovirus B19 infection is needed. Objective: This review describes the risks associated with parvovirus B19 infection during pregnancy and the management strategies for fetuses with vertically transmitted infections. Evidence Acquisition: Original articles were obtained from literature search in PubMed, Medline, and OVID; pertinent articles were reviewed. Results: Parvovirus B19 is a viral infection associated with negative pregnancy outcomes. Up to 50% of people of reproductive age are susceptible to the virus. The incidence of B19 in pregnancy is between 0.61% and 1.24%, and, overall, there is 30% risk of vertical transmission when infection is acquired during pregnancy. Although most pregnancies progress without negative outcomes, viral infection of the fetus may result in severe anemia, congestive heart failure, and hydrops fetalis. In addition, vertical transmission carries a 5% to 10% chance of fetal loss. In pregnancies affected by fetal B19 infection, Doppler examination of the middle cerebral artery peak systolic velocity should be initiated to surveil for fetal anemia. In the case of severe fetal anemia, standard fetal therapy involves an intrauterine transfusion of red blood cells with the goal of raising hematocrit levels to approximately 40% to 50% of total blood volume. One transfusion is usually sufficient, although continued surveillance may indicate the need for subsequent transfusions. There are fewer epidemiologic data concerning neonatal risks of congenital parvovirus, although case reports have shown that fetuses with severe anemia in utero may have persistent anemia, thrombocytopenia, and edema in the neonatal period. Conclusions and Relevance: Parvovirus B19 is a common virus; seropositivity in the geriatric population reportedly reaches 85%. Within the pregnant population, up to 50% of patients have not previously been exposed to the virus and consequently lack protective immunity. Concern for parvovirus B19 infection in pregnancy largely surrounds the consequences of vertical transmission of the virus to the fetus. Should vertical transmission occur, the overall risk of fetal loss is between 5% and 10%. Thus, understanding the incidence, risks, and management strategies of pregnancies complicated by parvovirus B19 is essential to optimizing care and outcomes. Further, there is currently a gap in evidence regarding delivery management, breastfeeding recommendations, and the risks of congenital abnormalities in pregnancies complicated by parvovirus B19. Additional investigations into optimal delivery management, feeding plans, and recommended neonatal surveillance are needed in this cohort of patients.
Asunto(s)
Hidropesía Fetal , Transmisión Vertical de Enfermedad Infecciosa , Infecciones por Parvoviridae , Parvovirus B19 Humano , Complicaciones Infecciosas del Embarazo , Humanos , Embarazo , Femenino , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Complicaciones Infecciosas del Embarazo/epidemiología , Complicaciones Infecciosas del Embarazo/virología , Complicaciones Infecciosas del Embarazo/terapia , Hidropesía Fetal/epidemiología , Hidropesía Fetal/etiología , Hidropesía Fetal/virología , Hidropesía Fetal/terapia , Infecciones por Parvoviridae/epidemiología , Infecciones por Parvoviridae/diagnóstico , Eritema Infeccioso/epidemiología , Eritema Infeccioso/diagnóstico , Eritema Infeccioso/terapia , Resultado del Embarazo/epidemiologíaRESUMEN
BACKGROUND: Parvovirus B19(B19) is a DNA virus. The most common B19 disease is erythema infectiosum (fifth-disease). PCR and ELISA are sensitive for detecting of acute disease. However, it is not clear which test better and the relationship between laboratory tests and clinical findings. OBJECTIVE: To discuss the clinical and laboratory characteristics of pediatric patients infected with B19. STUDY DESIGN: 236 children were examined. Children with at least one positive molecular or serological test were included. Positive serum B19-DNA and/or B19-IgM was considered an acute B19 infection. RESULTS: B19DNA was detected in 80.8 % of acute cases. Serological tests were less positive. Acute B19 infection was observed in 24 patients. Only 17 patients were positive for B19 DNA, 3 for IgM and 4 for both. The sensitivity of B19 DNA is 87.5 %. However, this rate is 29.2 % for B19 IgM. CONCLUSION: B19-DNA and IgM together provide a better, highly accurate diagnosis.
Asunto(s)
Anticuerpos Antivirales , ADN Viral , Eritema Infeccioso , Inmunoglobulina M , Parvovirus B19 Humano , Humanos , Parvovirus B19 Humano/genética , Parvovirus B19 Humano/inmunología , Parvovirus B19 Humano/aislamiento & purificación , Niño , Inmunoglobulina M/sangre , Preescolar , Femenino , Masculino , ADN Viral/sangre , Anticuerpos Antivirales/sangre , Eritema Infeccioso/diagnóstico , Eritema Infeccioso/sangre , Eritema Infeccioso/inmunología , Lactante , Sensibilidad y Especificidad , Adolescente , Reacción en Cadena de la Polimerasa/métodos , Infecciones por Parvoviridae/diagnóstico , Infecciones por Parvoviridae/sangre , Infecciones por Parvoviridae/inmunología , Infecciones por Parvoviridae/virología , Ensayo de Inmunoadsorción Enzimática , Pruebas Serológicas/métodosRESUMEN
Viral infections are major causes of mortality in solid-organ and hematopoietic stem cell transplant recipients. Epstein-Barr virus (EBV) and Parvovirus B19 (B19V) are among the common viral infections after transplantation and were recommended for increased screening in relevant guidelines. Therefore, the development of rapid, specific, and cost-effective diagnostic methods for EBV and B19V is of paramount importance. We applied Fluorescence of Loop Primer Upon Self-Dequenching Loop-mediated Isothermal Amplification (FLOS-LAMP) for the first time to develop a novel multiplex assay for the detection of EBV and B19V; the fluorophore attached to the probe are self-quenched in unbound state. After binding to the dumbbell-shaped DNA target, the fluorophore is dequenched, resulting in fluorescence development. The novel multiplex FLOS-LAMP assay was optimized by testing various ratios of primer sets. This novel assay, with great specificity, did not cross-react with the common virus. For the detection of EBV and B19V, the limits of detection could reach 969 and 798 copies/µL, respectively, and the assay could be completed within 25 min. Applying this novel assay to detect 200 clinical transplant individuals indicated that the novel assay had high specificity and good sensitivity. We developed multiplex FLOS-LAMP assay for the detection of EBV and B19V, which has the potential to become an important tool for clinical transplant patient screening.
Asunto(s)
Infecciones por Virus de Epstein-Barr , Herpesvirus Humano 4 , Técnicas de Diagnóstico Molecular , Técnicas de Amplificación de Ácido Nucleico , Parvovirus B19 Humano , Sensibilidad y Especificidad , Humanos , Herpesvirus Humano 4/genética , Herpesvirus Humano 4/aislamiento & purificación , Técnicas de Amplificación de Ácido Nucleico/métodos , Parvovirus B19 Humano/genética , Parvovirus B19 Humano/aislamiento & purificación , Infecciones por Virus de Epstein-Barr/diagnóstico , Infecciones por Virus de Epstein-Barr/virología , Técnicas de Diagnóstico Molecular/métodos , Fluorescencia , Cartilla de ADN/genética , Receptores de Trasplantes , Infecciones por Parvoviridae/diagnóstico , Infecciones por Parvoviridae/virología , ADN Viral/genética , Trasplante de ÓrganosRESUMEN
OBJECTIVE: Canine enteric coronavirus (CCV) and canine parvovirus type 2 (CPV-2) are the main pathogens responsible for acute gastroenteritis in dogs, and both single and mixed infections are common. This study aimed to establish a double-labeling time-resolved fluorescence immunoassay (TRFIA) to test and distinguish CCV and CPV-2 diseases. METHODS: A sandwich double-labeling TRFIA method was established and optimized using europium(III) (Eu3+)/samarium(III) (Sm3+) chelates. CCV/CPV-2 antigens were first captured by the immobilized antibodies. Then, combined with Eu3+/Sm3+-labeled paired antibodies, the Eu3+/Sm3+ fluorescence values were detected after dissociation to calculate the CCV/CPV-2 ratios. The performance, clinical performance and methodology used for laboratory (sensitivity, specificity, accuracy and stability) testing were evaluated. RESULTS: A double-label TRFIA for CCV and CPV-2 detection was optimized and established. The sensitivity of this TRFIA kit was 0.51 ng/mL for CCV and 0.80 ng/mL for CPV-2, with high specificity for CCV and CPV-2. All the accuracy data were less than 10%, and the recovery ranged from 101.21 to 110.28%. The kits can be temporarily stored for 20 days at 4 °C and can be stored for 12 months at temperatures less than - 20 °C. Based on a methodology comparison of 137 clinically suspected patients, there was no statistically significant difference between the TRFIA kit and the PCR method. Additionally, for CCV detection, the clinical sensitivity was 95.74%, and the clinical specificity was 93.33%. For CPV-2 detection, the clinical sensitivity was 92.86%, and the clinical specificity was 96.97%. CONCLUSION: In this study, a double-label TRFIA kit was prepared for CCV and CPV-2 detection with high laboratory sensitivity, specificity, accuracy, stability, clinical sensitivity and specificity. This kit provides a new option for screening/distinguishing between CCV and CPV-2 and may help improve strategies to prevent and control animal infectious diseases in the future.